Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its board of directors has authorized a share repurchase program of up to $2.5 million of the company's outstanding common stock.

The healthcare technology company expects to execute the repurchase program over the next 12 months. The timing, volume, and nature of repurchases will be determined based on factors including market conditions, share price, liquidity, and operational priorities. The program does not obligate the company to acquire any specific number of shares and may be suspended, modified, or discontinued at any time.

Aclarion intends to fund the repurchase program using existing cash and cash equivalents. As of March 31, 2026, the company had cash and cash equivalents of approximately $19.0 million.

"This authorization underscores our commitment to disciplined capital allocation and our belief that Aclarion's current valuation does not fully reflect the strength of our platform and long-term growth opportunity," said Brent Ness, chief executive officer of Aclarion.

Greg Gould, chief financial officer, stated that management believes the current capital position provides sufficient runway to support operations through key upcoming milestones, including the initial milestone of the CLARITY randomized trial.

Repurchases under the program may be executed through various methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or pursuant to Rule 10b5-1 trading plans, in compliance with applicable federal and state securities laws.

Aclarion develops healthcare technology that leverages biomarkers and artificial intelligence algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain.